奥沙利铂联合FL方案与FLP方案治疗进展期胃癌近期疗效观察

目的　评价奥沙利铂联合FL方案治疗进展期胃癌近期疗效与安全性。方法　 66例进展期胃癌患者随机分为治疗组和对照组各 3 3例。治疗组应用奥沙利铂 80mg/m2 静脉滴注第 1、8、15天 ,5 氟脲嘧啶 5 0 0mg/m2 静脉滴注第 1、8、15天 ,甲酰四氢叶酸钙 10 0mg/d静脉滴注第 1、8、15天。对照组应用顺铂 3 3mg/m2 静脉滴注第 1、 8、 15天 ,甲酰四氢叶酸钙10 0mg/d静脉滴注第 1、8、15天 ,5 氟脲嘧啶 5 0 0mg/m2 静脉滴注第 1、8、15天。 2 8d为 1周期 ,4周期后评价疗效。结果　治疗组CR 2例 ,PR 16例 ,NC或SD 8例 ,PD 7例 ,总有效 (CR +PR)率 5 4 5 5 %。对照组CR 0例 ,PR 10例 ,NC或SD 18例 ,PD 5例 ,总有效 (CR +PR)率 3 0 3 0 %。 2组总有效率相比有显著差异 (P <0 0 5 )。与对照组相比 ,治疗组有感觉神经毒性而无肾毒性。结论　奥沙利铂联合FL方案治疗进展期胃癌有较好的近期疗效 ,副反应小。

WEEKLY DOSE OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC CANCER

Objective To evaluate the efficacy and safety of oxaliplat in combined with fluorouracil(5-FU) and leucovorin (LV) in the treatment of patie nts with advanced gastric cancer. Methods 66 patients with ad vanced gastric cancer were randomly divided into treatment group and control gro up (33 cases for each group). The treatment group was used oxaliplatin 80 mg/m 2 intravenous infusion (1st and 8th and 15th day) and fluorouracil 500 mg/m2 i ntravenous infusion (1st and 8th and 15th day) and leucovorin 100 mg/d intraveno us infusion (1th and 8th and 15th day). The control group was used cisplatin 33 mg/m2 intravenous infusion (1st and 8th and 15th day) and fluorouracil 500 mg/ m2 intravenous infusion (1st and 8th and 15th day) and leucovorin 100 mg/d int ravenous infusion (1st and 8th and 15th day). The clinical curative effect was e valuated after 4 cycles. Results In treatment group, there were 2 CR,16 PR, 8 NC or SD and 7 PD. The overall response rate was 54.55%. In contro l group, there were 10 PR, 18 NC or SD and 5 PD. The overall response rate was 3 0.30%. The overall response rate(54.55%) in treatment group was obviously high er than that (30.30%) in control group(P<0.05). Compared with control gro up, there was neurosensory toxicity but no kidney toxicity in treatment group. Conclusion Oxaliplatin combined with fluorouracil and leucovo rin was obviously short-term effect in the treatment of patients with advanced gastric cancer with mild toxicity.